ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meeting Abstracts
    • All Meetings
    • ACR Convergence 2026
    • PRSYM 2026
    • ACR Convergence 2025
    • Download Abstract Supplements
  • Keyword Index
  • My Favorites
    • View & print my favorites
  • Search

Home » Meeting Abstracts » ACR Convergence 2021

Abstract Number: 0536

The EIF4 Translational Inhibitor Pateamine a Improves Immunological and Neurological Functions in BXSB.yaa Lupus Mice

Gonzalo Gómez-Hernández1, Nieves Varela1, Harini Bagavant2, Guillermo Barturen1, Marta E. Alarcon-Riquelme1 and Maria Morell1, 1GENYO.Center for Genomics and Oncological Research, Granada, Spain, 2Oklahoma Medical Research Foundation, Oklahoma City, OK

Share on X (Twitter) Share on Facebook Share on LinkedIn Share on Email
Print

Meeting: ACR Convergence 2021

Keywords: Animal Model, autoimmune diseases, neuropsychiatric disorders, Systemic lupus erythematosus (SLE), Therapy, alternative

Session Information

Date: Sunday, November 7, 2021

Title: SLE – Animal Models Poster (0534–0540)

Session Type: Poster Session B

Session Time: 8:30AM-10:30AM

Background/Purpose: Systemic Lupus Erythematosus (SLE) is an autoimmune disease characterized by loss of tolerance and activation of the immune response. Clinical manifestations are heterogeneous and several organs can be affected including skin, joints, central nervous system and kidney. Traditional treatments include the use of hydroxychloroquine, glucocorticosteroids, immunosuppressive and more recently, biological drugs such as belimumab or rituximab. In the last decade new alternatives have been proposed based on targeting interferon and cytokines. Mouse models have been extremely helpful to test the efficacy of new SLE therapies. In this work we analyze the therapeutic potential of a natural compound, Patemina A (PatA) to treat SLE. Pat A is an inhibitor of the translation initiation process with immunosuppressive properties that has been tested successfully in cancer mouse models.

Methods: To test Pat A efficiency in SLE we used the BXSB.Yaa lupus model. Animals were treated for 8 weeks starting at the initial stages of disease (12 weeks). Sera was collected every three weeks and disease signs were followed. At the final point we performed serological analyses (cytokines and autoantibodies), flow cytometry on spleen to evaluate different cell populations, kidney histological and functional assays and behavioral tests to evaluate neuropsychiatric changes.

Results: Our data shows that Pat A treatment increases the survival rate and is able to reduce circulating levels of proinflammatory cytokines and autoantibodies. We also observed improvement of cognitive functions (learning/memory, and depression behavioral tests) together with a reduction of proinflammatory cytokines locally in the hippocampus.

Conclusion: These data suggests that translation inhibition improves lupus disease signs at the immunological and neurological levels opening a new line of research based on translation inhibition to treat lupus and other autoimmune diseases.


Disclosures: G. Gómez-Hernández, None; N. Varela, None; H. Bagavant, None; G. Barturen, None; M. Alarcon-Riquelme, None; M. Morell, None.

To cite this abstract in AMA style:

Gómez-Hernández G, Varela N, Bagavant H, Barturen G, Alarcon-Riquelme M, Morell M. The EIF4 Translational Inhibitor Pateamine a Improves Immunological and Neurological Functions in BXSB.yaa Lupus Mice [abstract]. Arthritis Rheumatol. 2021; 73 (suppl 9). https://acrabstracts.org/abstract/the-eif4-translational-inhibitor-pateamine-a-improves-immunological-and-neurological-functions-in-bxsb-yaa-lupus-mice/. Accessed .

ACR Meeting Abstracts - https://acrabstracts.org/abstract/the-eif4-translational-inhibitor-pateamine-a-improves-immunological-and-neurological-functions-in-bxsb-yaa-lupus-mice/

My Favorites

Save and print abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract (must have cookies enabled in browser). See saved favorites.

Abstract Policies

  • ACR Convergence Abstract Embargo Policies
  • ACR Convergence Abstract Permissions & Reprints
  • PRSYM Abstract Policies

ACR Convergence. Where Rheumatology Meets

ACR Convergence 2026

Join us November 6-11 in Orlando, Florida.
See Registration Information

  • Contact ACR
  • Privacy Policy
  • ACR Policies
  • Cookie Preferences

© Copyright 2026 American College of Rheumatology